CMO HY23: NPAT down 21% as operating cash outflow widens to NZ$50.7m

What changed

Revenue from continuing operations fell 6.5% to NZ$500.9m, with trading profit before tax down 21.0% to NZ$20.9m and NPAT down 21.0% to NZ$14.3m. The operating segment, which is effectively the whole group, saw its result fall to NZ$19.8m from NZ$25.7m, with implied trading margin compressing from roughly 4.8% to around 4.0%. Operating cash flow swung from a NZ$1.5m outflow in HY22 to a NZ$50.7m outflow, driven in large part by inventories rising 16.4% to NZ$197.3m. The cash position still improved to NZ$16.1m, funded by a NZ$60.0m financing inflow. Gross borrowings eased to NZ$105.8m, leaving net debt at NZ$89.7m versus NZ$95.7m. The interim dividend was held at 15 cents per share.

What matters

• Cash conversion deteriorated materially. Operating cash outflow widened from NZ$1.5m to NZ$50.7m against broadly positive accounting earnings. Inventory grew by NZ$27.8m year-on-year, consistent with management commentary that shipping arrivals are dictating the timing of sales. This is a timing/working-capital issue on its face, but it is the dominant feature of the result.
• Margin compression, not just revenue softness. PBT fell 21% on revenue down only 6.5%, so operating leverage went the wrong way. The effective tax rate was stable at 28.1% (versus 28.4%), so the earnings decline is operational rather than tax-distorted. ROE weakened to 4.7% from 6.7%.
• Leverage and equity still strengthening. Despite the cash drag, net debt fell NZ$6.0m year-on-year and equity rose 11.8% to NZ$302.7m. The half-year payout ratio rose to 34.3% of NPAT (from 27.1%) purely because earnings fell, not because the Board lifted the distribution.

Expectations

No explicit earnings or revenue guidance, medium-term target or forward-order book was disclosed in the supplied release. Seasonality context from FY22 is mixed: HY22 represented 59.4% of FY22 revenue but 72.9% of FY22 NPAT, so the prior year was heavily first-half-weighted on earnings. On a simple run-rate basis, annualising HY23 revenue gives NZ$1.00b, about 11.2% above FY22's NZ$901.2m — but that read is only informative if inventory currently sitting on the balance sheet converts to second-half sales. The release does not support or refute a full-year earnings path beyond management's characterisation that trading profit was "the second highest on record."

Quality of result

Earnings quality is mixed. The NPAT decline is clean in the sense that it is not tax-assisted and no non-recurring items were flagged. However, the gap between accounting profit and operating cash is unusually wide: a NZ$14.3m NPAT alongside a NZ$50.7m operating cash outflow implies a working-capital absorption that is not yet monetised. Whether this is durable or timing-driven depends entirely on whether the NZ$197.3m inventory position clears in H2 at current margins. Balance-sheet strength (lower net debt, higher equity, NTA per share up to NZ$9.10 from NZ$8.13) is genuine. The flat dividend, however, is being paid out of a materially weaker cash result for the half.

Unresolved

• How much of the NZ$27.8m inventory build is committed stock awaiting delivery versus unsold finished goods at risk of margin compression?
• What is the gross margin trajectory underneath the trading-margin compression, given no gross margin or cost-of-sales split was provided?
• With floorplan finance stepping up (NZ$73.5m versus NZ$55.9m prior), how sensitive is H2 earnings to interest cost on that facility?
• Is the corporate segment contribution that appeared in HY22 (NZ$0.8m) genuinely absent in HY23, or reclassified?
• No capex, free cash flow, trade debtors, customer concentration or FX disclosure was provided in the extraction, so this briefing cannot assess underlying free cash flow, receivables quality, or the sensitivity of the import-dependent model to currency movement.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.